Streetbeat News

Earnings

OLO

Olo (NYSE:OLO) reported Q3 earnings of $0.04 per share, meeting analyst consensus. This is a 100% increase from the same period last year. The company also reported quarterly sales of $57.79 million, beating the analyst consensus estimate of $56.31 million by 2.64%. This is a 22.27% increase from the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 06, 2023 | 9:30 pm

COMP

Compass has projected its Q4 revenue to be between $1.1 billion and $1.2 billion, which is in line with the estimated $1.17 billion.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:29 pm

AZPN

Aspen Technology has issued its fiscal 2024 guidance, predicting an EPS of $6.57, slightly below the estimated $6.58. The company also expects a revenue of $1.12B, lower than the estimated $1.15B. Other projections include an ACV1 growth of at least 11.5% year-over-year, GAAP operating cash flow of at least $378 million, and total bookings of at least $1.04 billion.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:29 pm

GMRE

Global Medical REIT (NYSE:GMRE) reported Q3 2023 earnings of $0.23 per share, down 8% YoY. The company's quarterly sales were $35.49 million, missing the analyst consensus estimate of $36.00 million by 1.43%.

Portfolio Pulse from totan@benzinga.com

November 06, 2023 | 9:28 pm

MGNX

Macrogenics reported Q3 earnings of $0.28 per share, beating the analyst consensus estimate of $(0.10) by 380 percent. However, the company's quarterly sales of $10.40 million missed the analyst consensus estimate of $48.86 million by 78.72 percent.

Portfolio Pulse from bharat@benzinga.com

November 06, 2023 | 9:28 pm

STEP

StepStone Group (NASDAQ:STEP) reported Q2 2024 earnings of $0.26 per share, missing the analyst consensus estimate of $0.28 by 7.14%. This is a 21.21% decrease from the same period last year. The company also reported quarterly sales of $149.80 million, missing the analyst consensus estimate of $152.45 million by 1.74%, a 0.56% decrease from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 06, 2023 | 9:27 pm

NPCE

NeuroPace (NASDAQ:NPCE) reported Q3 earnings per share (EPS) of $(0.28), beating the analyst consensus estimate of $(0.41) by 31.71%. This is a 41.67% increase over losses from the same period last year. The company also reported quarterly sales of $16.43 million, beating the analyst consensus estimate of $14.22 million by 15.52%. This is a 47.23% increase over sales from the same period last year.

Portfolio Pulse from mahesh@benzinga.com

November 06, 2023 | 9:27 pm

COMP

Compass (NYSE:COMP) reported Q3 losses of $(0.08) per share, a 77.78% increase from $(0.36) per share YoY. Quarterly sales were $1.34 billion, missing the analyst consensus estimate by 0.15% and marking a 10.45% decrease from $1.49 billion YoY.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:27 pm

KIDS

OrthoPediatrics has reiterated its revenue guidance for FY23 to be in the range of $148.0 million to $151.0 million, representing a growth of 21% to 23% over 2022 revenue. The company also expects annual set deployments of approximately $23.0 million and $4.0 million to $5.0 million of adjusted EBITDA for the full year of 2023.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:26 pm

VYGR

Voyager Therapeutics reported Q3 losses of $(0.59) per share, missing the analyst consensus estimate of $(0.58) by 1.72 percent. This is a 231.11 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $4.61 million, beating the analyst consensus estimate of $2.91 million by 58.56 percent. This is a 88.77 percent decrease over sales of $41.09 million the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 06, 2023 | 9:26 pm